Sanofi appoints chief strategy officer

To cover all group business development activities

Sanofi has appointed Dr David-Alexandre Gros as chief strategy officer. He takes over the role on 1 September, reporting to chief executive Christopher Viehbacher. He will also join the group executive committee and be based in Paris, France.

Gros’ role will cover all group business development and acquisition activities, plus strategic planning, economic evaluation of projects, strategic intelligence, and alliance management.

Gros joins Sanofi after serving as an advisor to pharmaceutical, biotechnology and diagnostic companies as a principal and founding member of the Healthcare Investment Banking division at Centerview Partners, in San Francisco, CA.

He holds a BA from Dartmouth College (1995), an MD from Johns Hopkins University School of Medicine (1999), and an MBA from Harvard Business School (2002).

You may also like

Research & Development

Sanofi's tolebrutinib meets primary endpoints in Phase III HERCULES MS trial

The therapeutic has the ability to delay the onset of confirmed disability progression in patients, which is significant area of unmet need in the MS patient population
Manufacturing

Implementing advanced manufacturing technologies for novel therapies

Michele Ghinizzini, Senior Vice President, Global Head of Engineering and Maintenance at Sanofi, explores the elements that enable the realistic implementation of advanced technologies in drug development and manufacturing
Finance

Sanofi finalises Inhibrx acquisition

The acquisition expands Sanofi’s AATD therapeutic pipeline
Digital

AI for drug development: Sanofi, Formation Bio and OpenAI collaborate to enhance R&D processes

The companies will combine their AI and drug development capabilities to get therapeutics to patients quicker
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Distribution

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti
Subscribe now